Abdul Moiz Siddiqi: Systematic Review Finds Comparable Outcomes for Ticagrelor and Prasugrel in ACS
Abdul Moiz Siddiqi, Bachelor of Medicine and Surgery at Dow Medical College, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Cardiology in Review, adding:
“Alhumdulillah, I am incredibly thrilled to announce my first ever publication!
Our paper ‘Comparative Efficacy and Safety of Ticagrelor and Prasugrel in Acute Coronary Syndrome’ is now published in the ‘Cardiology in Review‘ journal.
Key Takeaways:
- Prasugrel and ticagrelor demonstrated comparable clinical efficacy and safety profiles in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)
- All-cause mortality occurred in exactly 3.53 percent of patients in both treatment arms, showing zero statistical difference between the two drugs (P=0.66)
- No significant differences were observed across major secondary ischemic outcomes, including cardiovascular death, myocardial infarction, stent thrombosis or stroke
- There is no clear universal winner or drug hierarchy so clinicians should select the P2Y12 inhibitor based on specific patient traits, compliance factors (like once-daily versus twice-daily dosing), tolerability, and explicit contraindications
This is my first ever grand achievement in the field of medicine and research.
I am grateful to have worked alongside incredibly supportive, passionate and professional peers without whom this would not have been possible.
I am specially grateful to Muhammad Ahmed and Shaheer Bin Shafiq my mentors for believing in me and providing me the opportunity to work on this project.”
Title: Comparative Efficacy and Safety of Ticagrelor and Prasugrel in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials
Authors: Shafiq Shaheer Bin, Razzak, Muhammad Junaid Ahmed Muhammad, Khan Ghulam Taha, Siddiqi Abdul Moiz, Bilal Abdur Rafay, Tariq Mansoor Khubaib, Sohaib Asharib, Khan Muhammad Abdullah, Majid Mominah, Ahmed Taha, Abbasi Maham, Waqas Saad Ahmed
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease